Introduction: Marginal zinc (Zn) deficiency due to hyper-zincuria is possible in patients with diabetes mellitus (DM). Zn supplementation, therefore, can be regarded as a suitable "back up" strategy in the management of DM. In this 11-week double-masked clinical trial we investigated the effects of a low-strength Zn sulfate supplement on metabolic control indices in children with type I DM. Methods: Thirty-one 5-15 years children with at least 1.5 year DM history, without any other metabolic condition were randomly divided into Zn-supplemented (10 mg elemental Zn per day) and/or placebo groups after matching for sex, age and DM duration. Twenty-six children fulfilled the study. Weight, fasting blood sugar (FBS), glycosylated hemoglobin (HbA1c), total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c) and triglyceride (TG), levels were determined at the beginning and end of trial.Results: In Placebo group, HbA1c, FBS, TC, LDL-c, HDL-c and TG levels changed from 9.7±0.4 to 10±0.5%, 243±26 to 241±22 mg/dl, 160±6 to 154±7 mg/dl, 95±23 to 93±19 mg/dl, 51±4 to 45±2 mg/dl and 68±7 to 85±12 mg/dl, respectively. Corresponding values for Zn supplemented group were 9.9±0.5 to 10±0.5%, 250±23 to 217±36 mg/dl, 176±6 to 161±6 mg/dl, 113±19 to 91±14 mg/dl, 55±5 to 47±3 mg/dl and 88±12 to 95±13 mg/dl, respectively. Only serum LDL-c significantly decreased within Zn supplemented group (P<0.003.(Conclusion: It seems that low-dose Zn supplementation is a safe compensatory strategy for hyper-zincuria in patients with type I DM.